Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas.

ABSTRACT:

Background

Muscle-invasive bladder cancers (MIBCs) cause approximately 150 000 deaths per year worldwide. Survival for MIBC patients is heterogeneous, with no clinically validated molecular markers that predict clinical outcome. Non-MIBCs (NMIBCs) generally have favorable outcome; however, a portion progress to MIBC. Hence, development of a prognostic tool that can guide decision-making is crucial for improving clinical management of bladder urothelial carcinomas.

Methods

Tumor grade is defined by pathologic evaluation of tumor cell differentiation, and it often associates with clinical outcome. The current study extrapolates this conventional wisdom and combines it with molecular profiling. We developed an 18-gene signature that molecularly defines urothelial cellular diffe

SUBMITTER: Mo Q 

PROVIDER: S-EPMC6279371 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature